Androgen receptor and its splice variants in prostate cancer - Wikidata - wikimedia - TriplyDB

Androgen receptor and its splice variants in prostate cancer

Androgen receptor and its splice variants in prostate cancer

http://www.wikidata.org/entity/Q34199684

about

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Alternative splicing for diseases, cancers, drugs, and databases Abiraterone in the treatment of metastatic castration-resistant prostate cancer Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells Androgen receptor splice variants and prostate cancer: From bench to bedside.Androgen receptor antagonists in castration-resistant prostate cancer.Splicing variants of androgen receptor in prostate cancer.Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target.Genetic variation: effect on prostate cancer.Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer.Expression of androgen receptor splice variants in clinical breast cancers.Spongian diterpenoids inhibit androgen receptor activity Posttranslational modification of the androgen receptor in prostate cancer.An imaging agent to detect androgen receptor and its active splice variants in prostate cancer The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.Novel agents for castration-resistant prostate cancer: Early experience and beyond.Synthesis of magnetic molecularly imprinted polymers with excellent biocompatibility for the selective separation and inhibition of testosterone in prostate cancer cells.Androgen receptor-related diseases: what do we know?Drug discovery in advanced prostate cancer: translating biology into therapy.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells.Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.The androgen receptor gene mutations database: 2012 update.Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR.Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.Molecular and cellular mechanisms of castration resistant prostate cancer.Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

P2860

Q26739708-AB5374DF-0CBC-4DDC-BC70-7D0300020F75 Q26852848-9C824E2A-6B57-412C-8F73-8131AB6E368F Q26853635-A784E24E-D288-4679-8312-C10D2CE73F29 Q28539233-5C2856C9-2155-4A3B-89F6-77AF7874D056 Q33567024-8D2AEBDB-27D9-4083-9AD0-C0944A9630EB Q34323656-41D83F54-BFF2-4E0C-AF4A-BA09FFEDEA3F Q34448143-27250F04-A4A0-4AFA-A54A-D19DAC8C18B3 Q34499785-6BAC4D7D-473A-407C-B67D-37F5B06F7453 Q34663656-3C0713E3-F653-4D76-ACFA-D4E25C7C8FF4 Q34734595-0369B928-B47E-4C5C-A63C-20CC62786E77 Q35702322-1BFF4874-2DAF-4778-A938-4AC423FD35D9 Q35762232-B9164F48-9023-4D32-91C9-381CC6968A54 Q36575243-B908E5BF-9302-4132-B337-1FDBDD4ABD34 Q36689084-26D1E55C-07EF-4D59-9F90-08066EE23D25 Q37058937-FE57D38F-5005-4BC4-BBBB-DBD9B1CC415E Q37092022-06301EEE-320F-4E55-958B-D6E2626B551C Q37165574-BEFAA5A0-6A2A-4892-B264-8839D59D7EEB Q37626493-0D968A65-D322-41EE-BCF5-6876DB021876 Q37697163-CCF8E0DC-BB1B-4E10-849F-58A1023374B7 Q38116358-E9F94739-C40D-4A6C-B90F-A55DAD5B87CA Q38181433-0D1C199E-485B-43FE-94FB-F36DF905B92E Q38184622-261A3560-1265-427E-93F6-95E37158D45D Q38361928-93F51FA7-E54E-42B2-A541-C72DA38C96C8 Q38574684-E7B790E9-9605-4B8C-8264-4B8ABA50DF39 Q38706080-AAE80B75-D61B-41E8-BB3E-4D65C9DD0D06 Q38780007-EFFB0FD9-1975-4A84-A03A-CBE8EAF3EE9B Q38839110-2CDE261E-4629-4CB6-BA21-85AF39B48205 Q38865487-EEA6EEFF-8192-4BCB-B020-1B669F479B2D Q39251637-F79185DF-93F1-4ECF-BD7D-D44AC7B82B1F Q39390992-D7B2CFE6-B7F4-4D53-805A-08E53E620BD2 Q39391441-69524E7A-267C-4D51-9BBF-1045731EB908 Q39652410-7695E458-0D20-47C5-902A-1BCA6F464EDB Q42878519-ADC1516D-AB08-4606-8571-B8850270FDF8 Q43211192-26A838AA-DEF0-477B-8EFB-4F13A7A4F644 Q47359141-F260D479-A410-4626-8516-65DAA5975968 Q48116656-39927206-1FAF-4010-9A08-E1E9CB4A2FFB Q49787526-2D88205E-8659-4038-9AEE-4A8EE53B995E Q52608488-5E93AF49-ECBF-4F79-B50D-6E3620A9441E Q57135992-00F1DFA2-693D-4535-AEEE-8A911A8CF6B5 Q58708797-7C4E4EA5-3248-477E-A3AD-0C1D5AA42271

P2860

Androgen receptor and its splice variants in prostate cancer

http://www.wikidata.org/entity/Q34199684

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Androgen receptor and its splice variants in prostate cancer

@ast

Androgen receptor and its splice variants in prostate cancer

@en

Androgen receptor and its splice variants in prostate cancer

@nl

type

label

Androgen receptor and its splice variants in prostate cancer

@ast

Androgen receptor and its splice variants in prostate cancer

@en

Androgen receptor and its splice variants in prostate cancer

@nl

prefLabel

Androgen receptor and its splice variants in prostate cancer

@ast

Androgen receptor and its splice variants in prostate cancer

@en

Androgen receptor and its splice variants in prostate cancer

@nl

P1433

Q34199684-184FCA24-C46A-4DA1-A859-5369CFF172DA

P1476

Q34199684-F2176B7B-5609-4851-86A9-C6A87963FFB1

P2093

Q34199684-34DE12E4-0450-470D-AC90-7638ED229E25

P2860

Q34199684-0013C047-5AAC-439F-8745-CFAEAA400393

Q34199684-0933D680-731F-481C-A7FD-FCD4F0A2130A

Q34199684-09E84943-2A6E-4D42-8DF4-F3FB35294F90

Q34199684-113CA65F-A14B-4898-B869-48F5572F93D3

Q34199684-13084E95-42D4-4F32-ADA9-8E45C7F238B2

Q34199684-13DD89B5-333E-47C7-B5C0-0EEF7EDB0459

Q34199684-17FEBBE7-1599-4BE3-A15E-AE7CDBE72E7E

Q34199684-19CA2414-6E58-4F18-9860-94EEB832A92B

Q34199684-1FABED71-A206-4CCE-9723-D9363DD7F995

Q34199684-24B9D4C6-42EA-44E1-B382-7499BD11E68F

P2888

Q34199684-DA983522-215A-4B7C-B7CC-93EF23871943

P304

Q34199684-B9E26D3F-AB72-4D21-80B2-511D9F63A9E1

P31

Q34199684-BDEBF26E-FDD3-4C93-BC9E-6B25E8241CD6

P356

Q34199684-124E11EC-0D7C-47E4-8513-6FE67DF4697E

P433

Q34199684-3DADAE94-8457-4FD8-A6F0-DFDAD13FC998

P478

Q34199684-DFE9F900-2B31-4B72-8EAD-FECA04FC2770

P50

Q34199684-299E6D08-0D61-49A3-AA75-51D2BDF2EBB6

P577

Q34199684-561EFFD7-E25F-455D-B738-6185350C230D

P698

Q34199684-3A3DAA83-6F33-4CAB-86EF-A700204DDC5B

P932

Q34199684-5578C1ED-7C13-44A2-907B-AEE410691329

P356

S00018-011-0766-7

P1433

Cellular and Molecular Life Sciences

P1476

Androgen receptor and its splice variants in prostate cancer

@en

P2093

Simon Haile

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

Molecular determinants of resistance to antiandrogen therapy

P2888

s00018-011-0766-7

P304

3971-3981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00018-011-0766-7

http://www.w3.org/2001/XMLSchema#string

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21748469

http://www.w3.org/2001/XMLSchema#string

P932

3729216

http://www.w3.org/2001/XMLSchema#string